Mixed Q1 Results for Tech and Healthcare as CEVA Leads with Licensing Growth

According to Q1 2026 earnings reports, Ceva announced an 11% revenue increase driven by its strongest licensing performance in three years, while Certara posted revenue of $106.9 million, a 1% year-over-year rise. Meanwhile, Exp World reiterated its full-year outlook following improved profitability metrics, and Bicara Therapeutics reported a strengthened cash position supported by a February public offering and clinical progress on its lead drug candidate.

This performance comes as semiconductor and biotech firms face mixed sector pressures, with market data showing relative stability despite interest rate volatility. Compared to previous quarters, Ceva's double-digit growth reflects a resurgence in the electronics IP market, aligning with broader industry trends where competitors have noted recovering demand for advanced design licenses per recent sector earnings analysis.

Looking ahead, investors are monitoring key economic catalysts that could impact growth stocks, including U.S. Initial Jobless Claims scheduled for May 7, 2026. With markets holding steady at the close of May 12, 2026, focus remains on whether these firms can maintain margins amidst labor cost pressures, which stood at 2.3% in the latest quarterly data according to the economic calendar.